Leukemia Research
Volume 33, Issue 12 , Pages 1658-1663 , December 2009

Identification of annexin 1 as a PU.1 target gene in leukemia cells

  • Yuko Iseki

      Affiliations

    • Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Sagamihara City, Kanagawa 228-8555, Japan
    • These authors contributed equally to this work.
    • ,
  • Akemi Imoto

      Affiliations

    • Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Sagamihara City, Kanagawa 228-8555, Japan
    • These authors contributed equally to this work.
    • ,
  • Toshio Okazaki

      Affiliations

    • Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Sagamihara City, Kanagawa 228-8555, Japan
    • Division of Hematology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Sagamihara city, Kanagawa 228-8555, Japan
    • ,
  • Hideo Harigae

      Affiliations

    • Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Japan
    • ,
  • Shinichiro Takahashi

      Affiliations

    • Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Sagamihara City, Kanagawa 228-8555, Japan
    • Division of Hematology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Sagamihara city, Kanagawa 228-8555, Japan
    • Corresponding Author InformationCorresponding author at: Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, Division of Hematology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Sagamihara City, Kanagawa 228-8555, Japan. Tel.: +81 42 778 8216; fax: +81 42 778 8216.

Received 19 January 2009 ,Revised 12 March 2009 ,Accepted 7 April 2009.

References 

  1. Chen HM, Zhang P, Voso MT, Hohaus S, Gonzalez DA, Glass CK, et al. Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood. 1995;85:2918–2928
  2. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265:1573–1577
  3. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36:624–630
  4. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta. 1994;1197:63–93
  5. Moss SE. Ion channels. Annexins taken to task. Nature. 1995;378:446–447
  6. Rothhut B. Participation of annexins in protein phosphorylation. Cell Mol Life Sci. 1997;53:522–526
  7. Alldridge LC, Harris HJ, Plevin R, Hannon R, Bryant CE. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem. 1999;274:37620–37628
  8. Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, Rodriguez-Ariza A, et al. Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics. 2006;6(Suppl. 1):S293–S299
  9. Inomata M, Takahashi S, Harigae H, Kameoka J, Kaku M, Sasaki T. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias. Leuk Res. 2006;30:659–664
  10. Takahashi S, Harigae H, Kameoka J, Sasaki T, Kaku M. AML1B transcriptional repressor function is impaired by the Flt3 internal tandem duplication. Br J Haematol. 2005;130:428–436
  11. Hirosawa M, Nakahara M, Otosaka R, Imoto A, Okazaki T, Takahashi S. The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res. 2009;33:693–699
  12. Takahashi S, Harigae H, Kaku M, Sasaki T, Licht JD. Flt3 mutation activates p21(WAF1/CIP1) gene expression through the action of STAT5. Biochem Biophys Res Commun. 2004;316:85–92
  13. Sakurai D, Yamaguchi A, Tsuchiya N, Yamamoto K, Tokunaga K. Expression of ID family genes in the synovia from patients with rheumatoid arthritis. Biochem Biophys Res Commun. 2001;284:436–442
  14. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol. 1996;52:433–439
  15. Takahashi S, Harigae H, Ishii KK, Inomata M, Fujiwara T, Yokoyama H, et al. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. Leuk Res. 2005;29:893–899
  16. Ishizawa K, Obara Y, Seki O, Fujimaki S, Kameoka J, Ichinohasama R, et al. Detection of bone marrow infiltration of lymphoma cells by fluorescence in situ hybridization. Clin Chim Acta. 2004;344:79–82
  17. Nogueira MM, Mitjavila-Garcia MT, Le Pesteur F, Filippi MD, Vainchenker W, Dubart Kupperschmitt A, et al. Regulation of Id gene expression during embryonic stem cell-derived hematopoietic differentiation. Biochem Biophys Res Commun. 2000;276:803–812
  18. Ge Y, Elghetany MT. CD36: a multiligand molecule. Lab Hematol. 2005;11:31–37
  19. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia. 2002;16:683–692
  20. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–1064
  21. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101:4667–4679
  22. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851–859
  23. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia. 2006;20:911–928
  24. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–1542
  25. Takahashi S, McConnell MJ, Harigae H, Kaku M, Sasaki T, Melnick AM, et al. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood. 2004;103:4650–4658
  26. Wlodarski P, Zhang Q, Liu X, Kasprzycka M, Marzec M, Wasik MA. PU.1 activates transcription of SHP-1 gene in hematopoietic cells. J Biol Chem. 2007;282:6316–6323
  27. Kihara-Negishi F, Yamamoto H, Suzuki M, Yamada T, Sakurai T, Tamura T, et al. In vivo complex formation of PU.1 with HDAC1 associated with PU. 1-mediated transcriptional repression. Oncogene. 2001;20:6039–6047
  28. Suzuki M, Yamada T, Kihara-Negishi F, Sakurai T, Hara E, Tenen DG, et al. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene. 2006;25:2477–2488
  29. Wu YL, Jiang XR, Lillington DM, Newland AC, Kelsey SM. Upregulation of lipocortin 1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells: a possible mechanism of resistance to immune surveillance. Br J Haematol. 2000;111:807–816
  30. Torlakovic EE, Bilalovic N, Golouh R, Zidar A, Angel S. Prognostic significance of PU.1 in follicular lymphoma. J Pathol. 2006;209:352–359
  31. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood. 2004;103:1901–1908

PII: S0145-2126(09)00187-8

doi: 10.1016/j.leukres.2009.04.010

Leukemia Research
Volume 33, Issue 12 , Pages 1658-1663 , December 2009

Article Tools

* Image Usage & Resolution